Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2023-02-21 17:18:25 UTC |
---|
HMDB ID | HMDB0015171 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Selegiline |
---|
Description | Selegiline, also known as L-deprenalin or zelapar, belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine. Selegiline is a very strong basic compound (based on its pKa). Selegiline is a potentially toxic compound. The compound without isomeric designation is Deprenyl. It is used in newly diagnosed patients with Parkinson's disease. A selective, irreversible inhibitor of Type B monoamine oxidase. Signs and symptoms of central nervous system stimulation, including convulsions, should be treated with diazepam, given slowly intravenously. |
---|
Structure | InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3 |
---|
Synonyms | Value | Source |
---|
Selegilina | ChEBI | Selegilinum | ChEBI | L-Deprenalin | HMDB | Bristol myers squibb brand OF selegiline | HMDB | Bristol-myers squibb brand OF selegiline | HMDB | L-Deprenyl | HMDB | Selegiline hydrochloride, (R)-isomer | HMDB | Selegiline, (R)-isomer | HMDB | Valeant brand OF selegiline | HMDB | Zelapar | HMDB | Hydrochloride, selegiline | HMDB | Selegiline hydrochloride | HMDB | Selegiline valeant brand | HMDB | Selegiline, (S)-isomer | HMDB | Selegyline | HMDB | Deprenalin | HMDB | Eldepryl | HMDB | Humex | HMDB | Jumex | HMDB | Selegiline hydrochloride, (S)-isomer | HMDB | Deprenil | HMDB | Emsam | HMDB | Selegiline hydrochloride, (R,S)-isomer | HMDB | Selegiline, (R,S)-isomer | HMDB | Yumex | HMDB | Deprenyl | MeSH |
|
---|
Chemical Formula | C13H17N |
---|
Average Molecular Weight | 187.2808 |
---|
Monoisotopic Molecular Weight | 187.136099549 |
---|
IUPAC Name | methyl(1-phenylpropan-2-yl)(prop-2-yn-1-yl)amine |
---|
Traditional Name | D-deprenyl |
---|
CAS Registry Number | 14611-51-9 |
---|
SMILES | CC(CC1=CC=CC=C1)N(C)CC#C |
---|
InChI Identifier | InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3 |
---|
InChI Key | MEZLKOACVSPNER-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Phenethylamines |
---|
Direct Parent | Amphetamines and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Amphetamine or derivatives
- Phenylpropane
- Aralkylamine
- Tertiary aliphatic amine
- Tertiary amine
- Acetylide
- Organic nitrogen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organonitrogen compound
- Amine
- Aromatic homomonocyclic compound
|
---|
Molecular Framework | Aromatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 141 - 142 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.025 g/L | Not Available | LogP | 2.7 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross SectionsAdduct Type | Data Source | CCS Value (Å2) | Reference |
---|
[M+H]+ | CBM | 142.1 | 30932474 |
|
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatized |
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Selegiline GC-MS (Non-derivatized) - 70eV, Positive | splash10-00r5-9200000000-2d93d82c982a8f156fde | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Selegiline GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Selegiline GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Selegiline LC-ESI-QFT , positive-QTOF | splash10-0006-9000000000-2501a3aa1587896c267f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Selegiline LC-ESI-QFT , positive-QTOF | splash10-0006-9000000000-e47889ea8699fd64eac5 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Selegiline LC-ESI-QFT , positive-QTOF | splash10-014u-4900000000-394f656868b3e600bd4c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Selegiline LC-ESI-QFT , positive-QTOF | splash10-00ko-7900000000-05e9bdebb41aefc9bdd7 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Selegiline LC-ESI-QFT , positive-QTOF | splash10-0006-9100000000-802ede31c15020d08f7d | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Selegiline 10V, Positive-QTOF | splash10-000i-0900000000-805c85cf8fffbddf9ce3 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Selegiline 20V, Positive-QTOF | splash10-00kk-6900000000-96dce81a4b7e4f517c3e | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Selegiline 40V, Positive-QTOF | splash10-0fr6-9300000000-75e40864b8dbd51d70d1 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Selegiline 10V, Negative-QTOF | splash10-000i-0900000000-24ba7e734753b5935dd4 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Selegiline 20V, Negative-QTOF | splash10-000i-2900000000-c504d7447caf055d67a7 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Selegiline 40V, Negative-QTOF | splash10-014l-9300000000-8b853bed043b95c3c6bb | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Selegiline 10V, Positive-QTOF | splash10-000i-2900000000-20851b32b820fc9ed460 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Selegiline 20V, Positive-QTOF | splash10-0006-9000000000-056944dbb701a5e7815a | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Selegiline 40V, Positive-QTOF | splash10-0006-9000000000-08554ca2f75d51e8c4cd | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Selegiline 10V, Negative-QTOF | splash10-000i-2900000000-b9c2210b820f3a4f784c | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Selegiline 20V, Negative-QTOF | splash10-00kf-9300000000-952f055a493d5c8adc44 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Selegiline 40V, Negative-QTOF | splash10-0gdl-9700000000-c1b8a392ffad5607d635 | 2021-10-11 | Wishart Lab | View Spectrum |
IR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+H]+) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+Na]+) | 2023-02-03 | FELIX lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB01037 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB01037 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | Not Available |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 5007 |
---|
KEGG Compound ID | C07245 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Selegiline |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 5195 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 50217 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583 ]
- Culpepper L, Kovalick LJ: A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Prim Care Companion J Clin Psychiatry. 2008;10(1):25-30. [PubMed:18311418 ]
- Macleod AD, Counsell CE, Ives N, Stowe R: Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898. [PubMed:16034956 ]
- Heinonen EH, Anttila MI, Lammintausta RA: Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):742-9. [PubMed:7995016 ]
- Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309. [PubMed:11978145 ]
- Engberg G, Elebring T, Nissbrandt H: Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J Pharmacol Exp Ther. 1991 Nov;259(2):841-7. [PubMed:1658311 ]
|
---|